title: A Lower-Cost Option for Intrauterine Contraception.
abstract: In March 2015, the U.S. Food and Drug Administration approved Liletta (Actavis, Dublin, Ireland), a new intrauterine device for contraception. The Centers for Disease Control and Prevention recommend use of long-acting reversible contraception (LARC) as first-line pregnancy prevention. LARC efficacy rates are similar to those of sterilization, with the possibility for quick return of fertility upon removal of the device. Despite benefits and recommendations for this form of contraception, access and high cost remain barriers to use. Liletta is the first lower-cost option for intrauterine contraception. Available to qualified clinics and health centers at a reduced rate, this device may increase availability and decrease the overall cost to women who desire intrauterine contraception.
authors.affiliation: W.F. Connell School of Nursing at Boston College in Chestnut Hill, MA, and a nurse at Massachusetts General Hospital in Boston, MA. Electronic address: pomerlek@bc.edu.
authors.forename: Kim
authors.initials: K
authors.lastname: Angelini
mesh_terms: D003267:Contraception / Q000295:instrumentation* / Q000379:methods; D017046:Cost Savings; D004867:Equipment Design; D004869:Equipment Safety; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000145:classification / Q000191:economics*; D011247:Pregnancy; D018873:Pregnancy Rate; D011275:Pregnancy, Unwanted; D014481:United States; D014486:United States Food and Drug Administration
keywords: LARC; Liletta; intrauterine contraception; long-acting reversible contraception